• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    GRAIL Appoints Sarah Krevans to Board of Directors

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent.

    CEO Sutter Health

    Ms. Krevans served as president and CEO of Sutter Health, a Northern California based not-for-profit health system in one of the most diverse and innovative regions in the nation, from 2016 to 2022. She was responsible for Sutter Health's integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Under her leadership, Ms. Krevans advanced clinical programs, innovation, and digital health to make healthcare more accessible for patients.

    "Sarah is a highly accomplished healthcare leader with extensive experience in a dynamic and diverse environment," said Bob Ragusa, CEO of GRAIL. "I am confident that her experience will bring immense value to GRAIL as we move toward establishing a new standard of care for multi-cancer early detection for patients."

    Previously, Ms. Krevans served as chief operating officer, and regional executive officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine's Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans' experience as a board member includes serving on many not-for-profit boards and as Chair of the California Association of Hospitals. She currently serves on the board of the Acacium Group and is the incoming Chair of CaringBridge.

    Ms. Krevans earned master's degrees in business administration and in public health from the University of California, Berkeley, and a bachelor's degree from Boston University. She has been named as one of the "Top 25 Women Leaders" by Modern Healthcare and included on Modern Healthcare's list of the "100 Most Influential People in Healthcare."

    About GRAIL

    GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

    For more information, visit grail.com.

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-appoints-sarah-krevans-to-board-of-directors-302282199.html

    SOURCE GRAIL, Inc.

    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent leadership change happened at GRAIL, Inc.?

      GRAIL, Inc. appointed Sarah Krevans to its Board of Directors effective immediately, bringing the total number of directors to five, with four being independent.

    • What was Sarah Krevans' role before joining GRAIL?

      Sarah Krevans previously served as the president and CEO of Sutter Health from 2016 to 2022, overseeing a large healthcare network in Northern California.

    • What contributions did Sarah Krevans make in her previous positions?

      Ms. Krevans is known for her strong background in healthcare leadership, having advanced clinical programs and digital health initiatives during her tenure at Sutter Health.

    • What is the primary mission of GRAIL, Inc.?

      GRAIL focuses on early cancer detection by utilizing next-generation sequencing and advanced machine learning techniques to identify multiple cancer types.

    • What ambitions does GRAIL have following the appointment of Sarah Krevans?

      Under Ms. Krevans' leadership, GRAIL aims to establish a new standard for multi-cancer early detection, benefiting patients with innovative healthcare solutions.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRAIL to Present at Jefferies Global Healthcare Conference 2025

      MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to

      5/21/25 4:05:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test

      MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution.

      5/12/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ofman Joshua J. sold $1,635,867 worth of shares (48,213 units at $33.93), decreasing direct ownership by 9% to 511,460 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 9:44:24 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Financial Officer Freidin Aaron sold $1,396,220 worth of shares (41,150 units at $33.93), decreasing direct ownership by 12% to 294,020 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:46:25 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Executive Officer Ragusa Robert P sold $3,190,608 worth of shares (94,035 units at $33.93), decreasing direct ownership by 11% to 734,627 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:44:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      10/10/24 7:45:32 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    SEC Filings

    See more
    • GRAIL Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - GRAIL, Inc. (0001699031) (Filer)

      5/16/25 4:05:53 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by GRAIL Inc.

      S-8 - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:21:27 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by GRAIL Inc.

      10-Q - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:11:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    See more
    • GRAIL Appoints Sarah Krevans to Board of Directors

      MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

      10/21/24 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/14/24 3:35:14 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/12/24 4:47:47 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

      SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

      9/30/24 6:42:39 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Financials

    Live finance-specific insights

    See more
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL to Announce First Quarter 2025 Financial Results

      MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves

      4/29/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results

      Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business

      2/20/25 4:02:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GRAIL with a new price target

      Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

      4/21/25 8:38:45 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Morgan Stanley initiated coverage on GRAIL with a new price target

      Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

      11/27/24 7:29:05 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on GRAIL

      Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

      11/15/24 7:46:11 AM ET
      $GRAL
      Medical Specialities
      Health Care